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I.  INTRODUCTION 
On June 07, 2000, President William J. Clinton issued an Administrative 
Declaration (hereinafter “the Declaration”) to then Health and Human Services 
Secretary Donna Shalala requiring Medicare to pay for the routine medical costs for 
Medicare recipients who were patients in clinical trials.2  There were, at the time, 
pending in Congress, several bills which would have required Medicare to pay these 
expenses, but all except one only required coverage of these expenses in clinical 
trials for cancer.  The “for cancer only” provision would create an irrational public 
policy that could in fact be harmful to progress against diseases other than cancer.  
The Declaration and its resulting regulations are not so limited; the President made 
the Declaration as a result of a report from the Institute of Medicine which argued 
that the President had the authority to make this change administratively.3 
There were also several pending proposals, differing in scope, before Congress 
which would have mandated private third party payers to cover routine care costs for 
clinical trial patients.  These proposals differed in that some were limited as to trial 
sponsor and some to trials for cancer therapy.  The two that passed their house of 
origin in Congress will be discussed in some detail.  The Bipartisan Patient 
Protection Act of 2001 (commonly referred to as McCain/Kennedy)4 was considered 
by the 107th Congress; it was nearly as broad in scope to private third party payers 
as the Clinton Declaration was regarding Medicare.  Some state legislatures have 
recently addressed the issue as well, and this article discusses their differing 
approaches.  Connecticut examined this issue, and the case study of this process 
supports the need for congressional action to create a uniform standard.   
This article examines the issue of coverage for routine medical expenses for 
clinical trial patients by third party payers from both a medical and political policy 
perspective.  It is critical for patients, investigators, and sponsors to know who is 
responsible for paying these costs.  This issue affects the willingness of patients to 
enter clinical trials and has the potential to affect which diseases will be the subjects 
of clinical trials.  This presentation first summarizes the basics of clinical trials and 
then explores the definition of routine care in clinical trials. Medicare 
                                                                
2Declaration, available at http://www.whitehouse.gov (last visited 1/17/01). 
3Institute of Medicine, Extending Medicare Reimbursement in Clinical Trials for Medicine 
(Henry J. Aaron & Hellen Gelband eds., National Academy Press, 2000). The Institute of 
Medicine is a part of the National Academy of Science which is an independent organization. 
4S. 283, 107th Cong. (2001). 
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reimbursement, an issue that has been the subject of recent decisive action, is the 
starting point.  The article provides explanation and discussion of the possible 
models, federal and state, for mandated coverage by other third party payers of 
routine patient care in clinical trials.  A policy discussion and analysis follow, which 
includes information on the potential effects of this change on third party payers as 
well as researchers and patients.  The placement of the cost liability for these 
expenses is related to other issues of patient protection; there is a brief discussion of 
the dangers of research on human subjects past and present to place this issue within 
the larger context of patient protection.  In general, this mandated coverage is 
sensible and would create good public policy.  However, it is important that patient 
protection remain the top priority in what could be an increased number of trials.  
The wording of the mandate should be careful not to shift costs that are rightfully 
borne by the trial sponsor to others. 
II.  WHAT ARE CLINICAL TRIALS? 
Clinical trials are part of the process that a new medical therapy (usually a drug 
or device) must undergo prior to approval by the Food and Drug Administration 
(FDA) and approved use by patients.  This is the part of the approval process in 
which the therapy is tested on human subjects.  The clinical trials generally have four 
phases.  Phase I is concerned primarily with safety; it requires only a small number 
of patients (generally 20 – 80) and determines safe dosage and monitors side effects.  
If the drug or device is found to be acceptably safe, the study moves to a Phase II 
trial which uses a larger number of patients (usually 100 – 300) and studies efficacy 
as well as safety.  Phase II does not compare the experimental therapy to any control 
group.  If Phase II shows a promising effect and does not appear to uncover any 
previously undetected safety issues, the trial moves to Phase III.   
Phase III is the mainstay of the clinical trial process.  In Phase III the treatment is 
given to a large number of patients (generally 1,000 – 3,000) often at multiple 
locations, and the new therapy’s effectiveness is compared either to a placebo or to 
the current standard treatment for the particular condition.  This phase monitors 
safety, confirms effectiveness, and compares the new therapy to those currently 
available (or to a placebo) in terms of both safety and efficacy.  This Phase is of 
extraordinary importance to the FDA when it decides whether to approve a new 
medical therapy.  Phase IV is conducted after the therapy is approved, and this Phase 
simply monitors the patients on the new therapy for a specified period of time after 
approval.5  
III.  WHAT ARE ROUTINE PATIENT CARE COSTS IN CLINICAL TRIALS? 
There are three basic types of costs associated with clinical trials: the cost of the 
investigational drug or device, the cost of data collection and analysis, and the cost 
of routine care for patient enrollees.6  The first two types of costs are traditionally 
borne by the clinical trial sponsor and this model is generally accepted with little 
disagreement.  The question of who should assume the routine care costs for patients 
in clinical trials remains a contentious issue in both medicine and politics.   
                                                                
5Http://www.clinicaltrials.gov; http://www.womens-health.org  
6Society for Women’s Health Research, Clinical Research: Who Should Pay for Routine 
Patient Care Costs?, June 19, 2000, at 4. 
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In order to implement President Clinton’s order, The Health Care Financing 
Administration (HCFA) posted a National Coverage Decision (NCD) for Medicare 
coverage of clinical trials.  After the posting the NCD and allowing comment, HCFA 
amended the Medicare Manual in September 2000 to include section 30-1.  
According to section 30-1:  
Routine costs of a clinical trial include all items and services that are otherwise 
generally available to Medicare beneficiaries (i.e. there exists a benefit category, it is 
not statutorily excluded, and there is not a national noncoverage decision) that are 
provided in a clinical trial except: 
*the investigational item or service, itself, 
*items and services provided solely to satisfy data collection and analysis needs 
and that are not used in the direct clinical management of the patient (e.g., monthly 
CT scans for a condition usually requiring only a single scan ); and 
*items and services customarily provided by the research sponsor free of charge 
for any enrollee in the trial. 
Routine costs in clinical trials include: 
*Items or services that are typically provided absent a clinical trial (e.g., 
conventional care), 
*Items or services required solely for the provision of the investigational item or 
service (e.g., administration of a noncovered chemotherapeutic agent), the clinically 
appropriate monitoring of the effects of the item or service, or the prevention of 
complications; and 
*Items or service needed for reasonable and necessary care arising from the 
provision of an investigational item or service — in particular, for the diagnosis or 
treatment of complications.7 
HCFA’s definition is at the broad end of the spectrum and includes significantly 
more coverage than some other suggested definitions of routine care. Not all of the 
proposed definitions are this clear.  HCFA was influenced by the Institute of 
Medicine (IOM) which supports a broad meaning of the term and defines routine 
patient care as, “Care that would be received by a patient undergoing ‘standard 
treatment.’  This would include such items as room and board for patients who are 
hospitalized, diagnostic and laboratory tests and monitoring appropriate to the 
patient’s condition, post surgical care when indicated, office visits, and so on.”8  
Section 30-1 simply expands on IOM’s suggested definition and adds details which 
provide clarity. 
Many of the definitions of routine care in proposed federal legislation as well as 
enacted by state legislation are consistent with HCFA’s definition, but less detailed.  
The varying versions of the Patients’ Bill of Rights that were proposed in the 106th 
Congress offered little detail.  The language from the House version of the Patients’ 
Bill of Rights in the 106th Congress is identical to that in the Bi-Partisan Patient 
Protection Act of the 107th Congress regarding clinical trial coverage.  That 
congressional language leaves significant discretion to the future rule making 
process: the plan or issuer “may not deny (or limit or impose additional conditions 
on) the coverage of routine patient costs for items and services furnished in 
                                                                
7Medicare manual § 30-1, adopted 9/2000. 
8See Institute of Medicine, supra note 3, at 70. 
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connection with participation in the trial.”9  The legislation that was proposed also 
offered a definition of what is not part of routine care:  “Routine patient costs do not 
include the cost of the tests or measurements conducted primarily for the purpose of 
the clinical trial involved.”10  The regulations that would have been required to 
implement this kind of federal legislation would have significantly affected the 
ultimate outcome of the policy.  
Generally the state statutes have taken a middle ground — not as much detail as 
the Medicare Manual, but more guidance than the Congressional proposals.  For 
example, New Hampshire’s statutes define routine care as, “The cost of any 
medically necessary health care service that is incurred as a result of the treatment 
being provided to a member of a health plan. Routine costs are those for which the 
health plan regularly reimburses its members, health care providers, or health care 
institutions subject to the terms and conditions of the member’s policy and the 
provider’s service agreement with the insurer.”11  The New Hampshire statute also 
defines non-routine costs:  
1. the cost of an investigational new drug or device that is not approved for 
market for any indication by the FDA   
2. the cost of a non-health care service that a member may be required to receive 
as a result of the treatment being provided for the purposes of the clinical trial. 
3. the costs that are clearly inconsistent with widely accepted and established 
regional or national standards of care for a particular diagnosis. 
4. costs associated with managing the research associated with the clinical trial. 
5. non-covered costs under the member’s policy plan or contract.12  
It is not clear from New Hampshire’s statutory language whether, say, the 
administration of the investigational therapy would be mandated — that will have to 
be worked out with time, government action, and possibly litigation. Most of the 
states that have drafted these proposals have definitions similar to these.   
Rhode Island which was the first state to take action on this issue, in contrast, did 
not include any definition of routine care in its statute.  The Rhode Island law states 
that, “Coverage shall be extended to new cancer therapies still under investigation 
when the following circumstances are met.”13  The statute proceeds to list conditions 
including trial qualifications and sponsorship.  It has no explicit statement 
eliminating the cost of the experimental drug and the trial-induced costs such as 
measurements.  Rhode Island’s statute is brief, but disconcertingly vague.14   
No definition can offer a clear answer for each and every claim submitted by a 
patient in a clinical trial, but the Medicare Manual provides a detailed definition, 
complete with examples which leaves less uncertainty than most of the available 
options.  
                                                                
9S. 283, 107th Cong. § 119; H.R. 2990, 106th Cong. § 1119.  Engrossed in the House.  
10Id. 
112000 N.H. Laws 415:18-k(i). 
12Id. at 18-k(h). 
13Id.  
141997 R.I. Pub. Laws § 27-18-36.2. 
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IV.  ARE THESE COSTS AFFORDABLE? HOW THE ROUTINE CARE COSTS FOR TRIAL 
PATIENTS COMPARE TO THOSE FOR PATIENTS RECEIVING STANDARD TREATMENT. 
Data that compare the routine care costs for patients in clinical trials with those 
of patients receiving standard treatment are somewhat scarce although they are now 
under examination.  The data that currently exist compare these costs for cancer 
patients only.  This is in large part due to the high level of government funding of 
cancer research.  There are four recent studies on this issue in oncology that show 
that the cost differences are not particularly significant. 
In August, 2000, the Journal of Clinical Oncology published the results of a pilot 
study which found that the medical care costs for clinical trial patients were slightly 
lower than those for non trial patients ($57,542 vs. $63,721).15  This was the pilot 
study for the Association of American Cancer Institutes/Northwestern University 
Clinical Trial Costs and Charges Project.  It compared data from 35 matched patient 
pairs in Phase II trials versus standard treatment.16  This is a work in progress and 
will yield significant additional data from a larger number of patients.  
The Journal of the National Cancer Institute (JNCI) recently published the results 
of two studies comparing routine care costs for clinical trial cancer patients with 
routine care costs for cancer patients receiving standard therapy.  One, published in 
January, 2000, examined the costs of medical care for 135 patients involved in 12 
clinical trials at a health maintenance organization (HMO), Kaiser Permanente, in 
northern California with 135 matched control subjects who were not enrolled in 
clinical trials.  This study measured the routine medical care costs for one year and 
showed that the overall cost for the clinical trial patients was 10% higher than for the 
non trial patients ($17,003 for trial patients and $15,516 for non trial patients).  
However, the study included a bone marrow transplant arm in which the medical 
care costs for the clinical trial patients were approximately double those for the non-
trial patients.  When the bone marrow transplant arm is left out of the analysis, the 
trial vs. non-trial costs are nearly identical ($15,041 for trial patients and $15,186 for 
non-trial patients).17 
In May, 1999 the JNCI published a cumulative 5-year cost study done at the 
Mayo Clinic in Minnesota which showed that trial enrollees incurred 3.5% to 13% 
higher costs than control patients over follow-up periods varying from 1 to 5 years.  
After 1 year, trial enrollee cost was $16,803 vs. control patient cost of $14,896.  The 
five-year costs was $28,853 vs. $27,870.18 
Although Vik Khanna of State Health Policy Solutions suggested that the RAND 
Corp. was in the process of a study that compares the medical care costs for clinical 
trial enrollees and non-trial patients that extend beyond cancer, the RAND study that 
                                                                
15Bennet et al., Evaluating the Financial Impact of Clinical Trials in Oncology: Results 
from a Pilot Study From the Association of American Cancer Institutes/Northwestern 
University Clinical Trials Costs and Charges Project, 18 J. OF CLINICAL ONCOLOGY 15, 2805-
10 (2000).  
16Id. 
17Bruce H. Firemen, et al., Cost of Care for Patients in Cancer Clinical Trials, 92 J. THE 
NAT’L CANCER INST. 7, (2000.). 
18Wagner, et al., Incremental Costs of Enrolling Cancer Patients in Clinical Trials: A 
Population Based Study, 91 JNCI 10, 847-53 (1999). 
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was recently published compared only patient care costs in cancer clinical trials 
versus patient care costs for cancer patients not enrolled in clinical trials.  This study 
showed that the routine patient care costs in cancer clinical trials are approximately 
6.5% higher than costs for cancer patients not enrolled in clinical trials.19  This study 
is in line with the rest of the available data.20 
Clearly, more extensive data are needed before a conclusive answer is evident. 
However, from the data that are currently available, the loss to third party payers 
appears to be minimal or at least manageable if there is, in fact, any loss at all. 
V.  WHAT IS THE STATUS OF THIRD PARTY PAYER REIMBURSEMENT FOR ROUTINE 
CARE COSTS FOR CLINICAL TRIAL PATIENTS CURRENTLY? 
A.  Medicare 
Prior to the Declaration, HCFA policy had been to deny reimbursement for 
routine care costs in clinical trials for Medicare beneficiaries.21  However, Medicare 
has unknowingly reimbursed for a significant percentage of these costs due in part to 
the fact that there is no way to indicate a patient’s clinical trial involvement on the 
Medicare forms.  The Institute of Medicine estimates that HCFA has actually 
reimbursed 50 percent of Medicare part B22 and 15 percent of Medicare part A.23 
HCFA has at times tried to enforce its non-reimbursement policy.  For example, 
in 1993 HCFA, suspecting that it had been mistakenly reimbursing for these 
expenses in certain device trials, requested an investigation by the Office of the 
Inspector General (OIG, which is within the Department of Health and Human 
Services (HHS)) to discover whether HCFA had been improperly paying for 
investigational medical devices.  The OIG’s finding was that providers had 
improperly billed Medicare.  What was determined to be improper was not merely 
the cost of the device but of the implantation as well.24 This divergence between 
policy (not to reimburse) and reality (reimbursing on a significant number of the 
claims) leaves the patients in an insecure position which discourages them from 
participating in clinical trials because of the fear of being responsible for their own 
care expenses.25  This uncertainty should now be resolved in light of the Declaration 
                                                                
19Goldman et. al, Incremental Treatment Costs in National Cancer Institute-Sponsored 
Clinical Trials, 289 J. OF THE AM. MED. ASSOC. 22, 2970-77 (June 11, 2003).  Note that the 
date used in this study was compiled before Medicare began paying routine patient care costs 
in clinical trials. 
20Prior to its publication, RAND would neither confirm nor deny that this study extends 
beyond cancer.  Vik Khanna of State Health Policy Solutions, LLP, stated that this study will 
extend beyond cancer at his presentation to the Connecticut Clinical Trials Task Force 
meeting on July, 2000. 
21See Institute of Medicine, supra note 3, at 31; General Accounting Office, Cancer 
Clinical Trials: Medicare Reimbursement Denials, GAO/HEHS-98-15R, at 1 (1998). 
22Medicare part B is outpatient care, doctor’s office visits, etc. 
23Medicare Part A is essentially hospital insurance. 
24Institute of Medicine, supra note 3, at 32-33. 
25Id. 
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and section 30-1 of the Medicare Manual; it is too early to know what the effects will 
be. 
B.  Other Third Party Payers   
There is a great deal of variation between health plans regarding coverage of 
routine care costs for clinical trial patients.26  The changes in our healthcare delivery 
system that have spawned for-profit Managed Care Organizations have changed the 
perspective of a significant percentage of third party payers toward the ancillary 
costs of clinical trials.27  Additionally, the increasing use of clinical trials to 
investigate potential new therapies has vastly increased the magnitude of this 
dispute.28  It is somewhat difficult to gain an accurate statistical picture of how these 
costs are paid because some of the routine patient care is submitted to the third party 
payers with no designation that it is related to a clinical trial.29   
In general, there appears to be a downward trend in reimbursement for routine 
care expenses for clinical trial patients by third party payers.  Dr. Seth A. Rudnick at 
the October 1996 meeting of the President’s Cancer Panel asserted that the 
downward trend is quite sharp.  According to Dr. Rudnick, third party payers 
covered 80 percent of routine patient care costs in 1970, 70 percent in 1990, and only 
50 to 65 percent in 1996.30  The Blue Cross Blue Shield Association (BCBSA) 
conducted a study of HMOs in 1997 which showed a similar trend,31 but the BCBSA 
declined to release the report. 
VI.  WHAT ARE THE POSSIBLE MODELS FOR COVERAGE OF ROUTINE PATIENT CARE 
COSTS IN CLINICAL TRIALS? 
The varying proposals for coverage of clinical trial patients’ routine care costs 
represent not merely alternative solutions to a common problem but rather these 
proposals represent sharply conflicting philosophies on the appropriate role of 
federal and state government.  The broadest end of the continuum would require all 
third party payers to cover these costs in both government sponsored and privately 
(generally drug or device manufacturing company) sponsored trials for all serious 
diseases.  The proposals at the narrow end of the continuum would affect only self-
insured Employee Retirement Income Security Act plans32 and cover only 
                                                                
26President’s Cancer Panel, FIGHTING THE WAR ON CANCER IN AN EVOLVING HEALTH CARE 
SYSTEM, National Cancer Inst. (1997).  Telephone interview with Ingrid Saphire-Bernstein , 
Manager of the Office of Clinical Affairs at the Blue Cross Blue Shield Ass’n (August 2000). 
27National Cancer Institute, supra note 22, at C-32. 
28Telephone Interview with Dr. Timothy Vollmer, Former Director of the Yale M.S. 
Research Center (August, 2000).  Dr. Vollmer is currently Chairman of Neurology at the 
Barrows Neurologic Institution in Phoenix, AZ. 
29Vik Khanna talk at July 19 meeting of the Connecticut Clinical Trials Task Force. See 
also Institute of Medicine, supra note 3.  President’s Cancer Panel, supra note 23.  
30National Cancer Institute, supra note 23, at C-32. 
31Cited in Society for Women’s Health Research, Clinical Research: Who Should Pay for 
Routine Patient Care Costs?, at 32 June 19, 2000. 
32The Employee Retirement Income Security Act of 1974 (ERISA) governs employer 
sponsored health plans and is discussed later in this article. 
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government sponsored cancer trials.  The proposals are presented under three general 
categories: A. Medicare; B. Federal Mandates; and, C. State Mandates.  The section 
on state mandates begins with an examination of recent happenings in Connecticut 
which has been working on the issue for the last two years; its story illuminates the 
need for a national uniform standard that can only be provided by Congress. 
Perhaps the most perplexing trend among the coverage models is the inclusion of 
a “for/cancer/only” provision.  Cancer is the subject of many clinical trials, but there 
is a greater chance that insurers already agree to cover the routine care for cancer 
trials because of agreements with NIH cooperative groups and because the American 
Association of Health Plans (AAHP) recommends that its members cover these costs 
for cancer.33  NIH cooperative groups generally are a formal network of facilities that 
collaborate on research projects including clinical trials and that have an NIH 
approved peer review program.  NIH is a partner but does not assume a dominant 
role.34  Often these groups are able to work out an agreement with the relevant third 
party payers to cover routine care costs.  In addition, cancer affects a large number of 
people which makes it attractive for pharmaceutical companies to sponsor cancer-
related drug trials.  Cancer receives an extraordinary amount of government support 
and is the subject of a large number of government-funded trials.  Less attention has 
been paid to those who argue that this coverage is most needed for rare diseases for 
which there are limited prospects for new research if the cost is prohibitive to the 
sponsor.  Dr. Timothy Vollmer warns that this policy allows insurers to discriminate 
against patients who have diseases without large politically active organizations, 
“they [the insurers] will continue to be able to reap profits from patients with rarer 
chronic illness simply because they are unlucky enough to have those diseases and 
that’s inappropriate.”35 
A.  Medicare  
President Clinton’s sweeping Declaration regarding Medicare superseded the 
more conservative legislation that was pending in Congress at the time of the 
Declaration.  President Clinton accepted the advice of the Institute of Medicine36 and 
did not limit the Declaration’s effect to a specific disease nor to publicly funded 
trials.  Medicare is government funded and so the prospect of requiring these 
payments does not raise the issue of federalism (i.e., whether the federal or state 
government has the power to require third party payer coverage).   
In the realm of government-sponsored trials this debate takes on the feeling of an 
intragovernmental squabble.  Since no one argues that the patients should pay, the 
debate is then whether the Health Care Financing Administration (HCFA), which 
administers Medicare, or the government agency sponsoring the research should pay 
these expenses.  The significance of the Declaration’s assignment of these costs 
(even for government-sponsored trials) to Medicare is that this sets a precedent for 
third party payers to assume routine care costs for clinical trial patients.  
                                                                
33See AAHP Board Statement on Clinical Trials (Dec. 11, 1988), at http://www.aahp.org.   
34See NIH Guide:  DCT Clinical Trials Cooperatives Groups, (May 26, 1995), available 
at http://grants.nih.gov/grants/guide/pa-files/PAR-95-063.html 
35Vollmer Interview, supra note 24. 
36Institute of Medicine, see supra note 3, at 55. 
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Medicare is an extraordinarily influential force in healthcare in the United States; 
there are 39 million residents of the U.S. who receive Medicare benefits and that 
number is growing as our population ages.37  Very often, other third party payers 
follow Medicare’s lead.  
At the time that President Clinton issued the Declaration, there was legislation 
pending in Congress that addressed the issue of Medicare coverage of routine care 
costs for clinical trial patients receiving Medicare: The Medicare Clinical Trials 
Mandate,38 and the Medicare Cancer Clinical Trials Mandate.39  Neither of these bills 
would have provided coverage as broad as the Declaration although each one 
contained fewer restrictions on the source of the sponsorship of the trial than the 
106th Congress’s proposed federal mandates which would affect other third party 
payers.  The 107th Congress’s proposal on the issue is broader than that of the 
106th—perhaps following Medicare’s lead.  These will be discussed in the next 
section.   
Both the House and Senate versions of the Medicare Cancer Clinical Trial 
Coverage Act of 1999 (S.784 and H.R. 1388) would have mandated coverage, as the 
title implies, only for cancer trials.  The cancer-only provision created some concern 
among groups that work with other clinical trial populations that this would decrease 
the likelihood for reimbursement of routine care expenses for patients in non-cancer 
clinical trials.40  The Medicare Clinical Trial Coverage Act of 1999 would, as the 
Declaration did, mandate coverage in clinical trials for all serious diseases.   
All of these legislative proposals that were superseded by the Declaration 
provided coverage for a more limited number of trials than the Declaration and its 
resulting section in the Medicare Manual does.  The pending legislation listed 
specific government sponsors that would qualify.  All included any trial approved by 
NIH, FDA, the Department of Veterans Affairs (VA), the Department of Defense 
(DoD), and qualified non-governmental research entities identified by NIH 
guidelines.  H.R. 61 also would have covered trials sponsored by the Department of 
Energy.  By specifically listing which governmental agencies are covered, the 
legislation leaves out some other agencies, such at the Centers of Disease Control, 
that also sponsor clinical trials.  The Declaration, because of its broad language does 
not limit trial sponsorship although to qualify the trial must be an approved one.    
HHS posted its proposed guidelines to implement the Declaration on August 4. 
2000,41 and the final NCD as well as the relevant section (30-1) of the Medicare 
                                                                
37Medicare Eligibility, Enrollment, and Premiums, at http://www.medicare.gov/basics/ 
overview.asp. 
38H.R. 61, 106th Cong. (1999). 
39S. 784, H.R. 1388, 106th Cong (1999). 
40Telephone interview with Jeanie Ireland, Senior Health Policy Advisor for U.S. Sen. 
Christopher Dodd (Aug., 2000). 
41The final coverage decision in the Medicare Manual varies slightly from the proposed 
national coverage decision posted on August 4, 2000.  The language from the proposed NCD 
defined routine care to include: 
*Items or services that are typically provided absent a clinical trial (e.g., conventional 
care), 
*Items or services required solely for the provision of the investigational item or 
service (e.g., administration of a noncovered chemotherapeutic agent), the clinically 
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Manual in September 2000. The Medicare coverage is broad and is consistent with 
the recommendations of the Institute of Medicine report.  To Reiterate, the Medicare 
Manual defines routine costs to include: 
Routine costs of a clinical trial include all items and services that are otherwise 
generally available to Medicare beneficiaries (i.e. there exists a benefit category, it is 
not statutorily excluded, and there is not a national noncoverage decision) that are 
provided in a clinical trial except: 
*the investigational item or service, itself, 
                                                          
appropriate monitoring of the effects of the item or service, or the prevention of 
complications; and 
*Items or service needed for reasonable and necessary care arising from the provision 
of an investigational item or service — in particular, for the diagnosis or treatment of 
complications.  
all items and services that are otherwise generally available to Medicare beneficiaries 
(e.g., hospital services, physician services, diagnostic tests) that are provided in a 
clinical trial except the investigational item or service, itself, items and services 
provided solely to satisfy data collection needs (protocol-induced costs), and items and 
services provided by the trial sponsor without charge.  
…[Examples] include:  
items or services that are typically covered in the absence of a trial (conventional 
care), Items or Services Required solely for the provision of the investigational item 
service (e.g., administration of a noncovered chemotherapeutic agent), the clinically 
appropriate monitoring of the effects of the item or service or the prevention of 
complications; and Items or services needed for reasonable and necessary care arising 
from the provision of an investigational item or service—in particular, for the 
diagnosis or treatment of complications.  
 
The guidelines propose “desirable characteristics of a trial” and request comments on the 
desirable characteristics.  The HCFA proposal lists: 
1. The principal purpose of the trial is to test whether the intervention potentially 
improves the participants’ health outcomes; 
2. The trial is well-supported by available scientific and medical information or it is 
intended to clarify or establish the health outcomes of interventions already commonly 
in clinical use; 
3. The trial does not unjustifiably duplicate existing studies; 
4. The trial design is appropriate to answer the research question being asked in the 
trial; 
5.  The trial is conducted according to appropriate standards of scientific inquiry. 
 
The guidelines also offer examples and request comments on questions which can be 
answered on a yes/no basis and would be of assistance in determining the desirability of a 
specific trial.  The examples offered in the guidelines are,  
Is the trial approved by an Investigational Review Board (IRB)? 
Does the trial have a written protocol? 
Has the trial been approved by a Federal agency? 
Has the trial received any external non-Federal funding? 
Has the trial been reviewed by any external, non-Federal group?  
Does a data safety and monitoring board provide independent oversight of the trial?  
 
Clearly the purposes of sections on desirable characteristics of a trial and on the criteria 
questions sections of the NCD are to ensure that the clinical trials eligible for reimbursement 
are reputable, with a good chance of success, and do not put the beneficiaries at undue risk.  
These sections are to ensure good quality control. 
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*items and services provided solely to satisfy data collection and analysis needs 
and that are not used in the direct clinical management of the patient (e.g., monthly 
CT scans for a condition usually requiring only a single scan ); and 
*items and services customarily provided by the research sponsor free of charge 
for any enrollee in the trial. 
Routine costs in clinical trials include: 
*Items or services that are typically provided absent a clinical trial (e.g., 
conventional care), 
*Items or services required solely for the provision of the investigational item or 
service (e.g., administration of a noncovered chemotherapeutic agent), the clinically 
appropriate monitoring of the effects of the item or service, or the prevention of 
complications; and 
*Items or service needed for reasonable and necessary care arising from the 
provision of an investigational item or service — in particular, for the diagnosis or 
treatment of complications.42 
The Medicare Manual offers a reasonable option for defining both routine care 
and a desirable trial.  If the final guidelines are as thoughtful and helpful, HCFA has 
the opportunity to lead both the federal and state governments in finding a sensible 
path on this issue. 
An Administrative Declaration can be easily reversed if, for example, President 
Bush objects to this policy interpretation.  For this reason some legislators may work 
to support the Declaration with decisive legislative action. 
B.  Proposed Federal Mandates 
1.  The 106th Congress Missed a Window of Opportunity  
The struggle over the various proposals for a Patients Bill of Rights in the United 
States Congress was a highly publicized debate in the 106th Congress.  In the end, of 
course, none of these proposals passed.  All versions of this legislation included 
some language pertaining to third party payer coverage of routine medical care costs 
for clinical trial patients.43  The differences among the proposals for coverage of 
routine patient care costs represented, in part, fundamentally different views of the 
appropriate role of the federal government.  
One of the significant differences among the proposals was which third party 
payers would be affected.  This difference affected all sections of the relevant 
versions of the Patients Bill of Rights.  The scope depended on which sections of 
The Employee Retirement Income Security Act of 1974 (ERISA) were targeted by 
the legislation. 
ERISA governs, among other things, group health plans which are established or 
maintained by employers or employee organizations and provide medical benefits to 
employees.  ERISA does not affect government employees, churches or church 
related facilities.  There are two types of ERISA group health plans: self-insured and 
fully-insured.  In a fully-insured ERISA plan, benefits are purchased from a health 
                                                                
42See Medicare manual § 30-1, (adopted Sept. 2000). 
43The more limited version was S. 1344 106th Cong. § 730 (1999) which is the same 
language as H.R. 2990, 106th Cong. § 730 (1999) that was engrossed in the Senate.  The 
broader version was H.R. 2990, 106th Cong. § 1119 engrossed in the House. 
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insurance issuer and the issuer is subject to all relevant state laws; therefore the state 
has some indirect control even though a state cannot regulate the plans directly due 
to ERISA’s strong preemption clause.44  
In Self-insured ERISA plans, claims are paid directly by the employer either 
from company assets or from a tax-exempt trust funded by some combination of 
employer/employee contribution.  Self-insured ERISA plans are completely shielded 
from any state regulation and are subject only to the regulations in ERISA.45  The 
more liberal version of the Patients Bill of Rights which passed the House of 
Representatives, and is referred to as the House Bill or Norwood/Dingell, would 
have affected both kinds of plans, thus creating one mandate for all third party 
payers.46  The more conservative legislation which passed the Senate and is referred 
to as the Senate Bill, would have only affected self-insured ERISA plans and left the 
regulation of fully insured ERISA plans to the states.47  The problem created by this 
states-rights approach would be the lack of a uniform national standard.  In fact, by 
leaving fully insured ERISA coverage at state option, there would be no guarantee 
that those covered by fully insured ERISA plans would receive this coverage at all.   
Both the House and Senate Bills limited the mandate to clinical trials sponsored 
by NIH, DoD, and the VA.  One effect of this limitation would be to prevent 
fraudulent trials from sprouting up to gain profit from this policy change.  These 
government sponsored trials must follow strict, but not foolproof, regulations 
concerning the treatment of human subjects.48  These ethical issues are the subject of 
discussion in a later section of this article. The limitation by sponsor may also have 
been an attempt to reduce the possible effect on the third party payers in the event 
that the policy is not revenue neutral as expected.  
The Senate Bill from the 106th Congress also limited the coverage mandate to 
one disease: cancer. The restriction to cancer trials reflects a conservative approach 
that claims to start with one disease in order to observe the effect of this type of 
mandated coverage and then use this information as part of a step by step approach.  
The choice of cancer as the target reflects the political influence of the advocacy 
organizations for that disease.  However, often it can be difficult to change such a 
policy once it is the norm,49 and the routine care expenses for patients in clinical 
trials for new cancer treatments are often covered now due to efforts such as NIH 
Cooperative groups. The Senate proposal would have given aid where it was needed 
least. 
                                                                
44Phyllis Borzi & Sara Rosenbaum, Prepared for the Kaiser Family Foundation, Pending 
Patient Protection Legislation: A Comparative Analysis of Key Provisions of the House and 
Senate Versions of H.R. 2990, (March 2000) at 32-33. 
45Id. 
46H.R. 2990, 106th Cong. § 1119 (1999). 
47S. 1344 106th Cong. § 730 (1999). 
4845 C.F.R. 46 (2002) governs these trials.  The trials must gain approval of an IRB, 
undergo peer review, and follow detailed ethical standards.   
49Telephone Interview with Jeanie Ireland, Senior Health Policy Advisor to Senator 
Christopher Dodd. (Aug. 2000).  Many members of Congress recognized this and fought for 
legislation that would include all serious diseases and all third party payers. 
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The House Bill would have required third party payers to cover routine patient 
medical care in clinical trials for serious or life threatening diseases for trials funded 
by NIH, DoD, and the VA.  This legislation was not limited to cancer, and it was not 
limited in effect to self-insured ERISA plans.  Norwood/Dingell reflected support for 
federal authority and a desire for a uniform national standard. 
Although the two bills discussed above were the only ones that passed their 
house of origin in 106th Congress, other policy options exist. One alternative that 
was proposed would have covered clinical trials for serious or life threatening 
diseases, private insurers and group health plans BUT only NIH and cooperative 
groups of NIH.50  This would have limited the impact on third party payers (which is 
desirable to some legislators) but would still have offered this moderate assistance to 
patients with diseases other than cancer. 
Another proposal would have contained a cancer-only provision but would have 
included FDA approved [privately sponsored] trials as well as government funded 
trials under mandated coverage.  This would greatly expand the liability of third 
party payers in scope, but limit it by disease — and again to the disease that needs 
this assistance least.   
Alternatively, a mandate could include FDA approved [privately sponsored] 
trials as well as government funded trials and cover all qualified clinical trials.  This 
would be as broad in scope and effect to other third party payers as the Declaration is 
for HCFA.  The 106th Congress seemed a bit leery to make a leap of this magnitude.  
On balance, the House proposal contained in the Norwood/Dingell Patients Bill of 
Rights might have been a logical starting point.  If this plan had been implemented 
and proven successful, Congress could have expanded the mandate to privately 
funded trials.   
2.  The 107th Congress Begins With a Broader Proposal, Perhaps Affected by the 
Strength of the Clinton Declaration, but Still Fails to Act in the End 
The 107th Congress began consideration of the Patient Protection Act of 2001 
shortly after the defection of Senator James Jeffords from the Republican Party 
which gave control of the Senate to the Democrats.  The future of this legislation 
appeared immediate and promising until the September 11, 2001 tragedy which put 
patients rights on the back burner for the moment.  This legislation addressed the 
issue of mandated coverage of routine patient care in clinical trials with Section 119 
of Senate Bill 283, The Bipartisan Patient Protection Act of 2001 
(McCain/Kennedy).  This section is nearly identical to Sec. 1119 of the 
Norwood/Dingell version of the Patients’ Bill of Rights from the 106th Congress.51  
The one clearly significant difference is that the McCain/Kennedy bill included all 
clinical trials for serious or life threatening conditions approved and funded by the 
FDA.52  Norwood/Dingell53 would have and McCain/Kennedy54 would also have 
mandated coverage for clinical trials for serious or life threatening conditions 
                                                                
50S. 6, 106th Cong. (1999) and H.R. 358, 106th Cong. (1999).  
51H.R. 2990, 106th Cong. 
52S. 283, 107th Cong. § 119(d)(1)(C) (2001). 
53H.R. 2990, § 1119(d)(1)(A) - (C). 
54S. 283, 107th Cong. § 119 (d)(1)(A) - (D). 
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approved and sponsored by NIH, Cooperative Groups of NIH, Veterans Affairs and 
Defense. 
The inclusion of the FDA would expand the mandate under this patient 
protection legislation to include privately funded trials—this provision would 
significantly increase the reach of the mandate.  It may well be that this expansion 
was fueled by the broad quality of the mandate in the Medicare Manual; Medicare is 
often influential in that way.   
Between the aftershocks of September 11, 2001 and the war with Iraq, this issue 
seems off the radar of the 108th Congress.  Now that the war is over, the Patients Bill 
of Rights may return to the agenda.  There is a bill in the 108th Congress, H.R. 597, 
the Patient Protection Act which addresses the clinical trial issue.  Section 119 of this 
bill is essentially identical to Sec. 119 of SB 283 of the 107th Congress.   
C.  Status In The States 
A number of states have addressed the issue of third party payer reimbursement 
for routine medical care costs of clinical trial patients.  One precursor to state 
requirements on clinical trial coverage was that prior to 1997 a few states (about 10) 
moved to require third party payer reimbursement for autologous bone marrow 
transplants for breast cancer patients.55  This treatment for breast cancer was often 
considered experimental and as such denied by insurance carriers.  From this 
mandated coverage, it was not a tremendous leap for legislatures to investigate 
mandated coverage of routine medical care costs for clinical trial patients.  Of course 
none of the state mandates affect self-insured ERISA plans in any manner 
whatsoever. 
The majority of states that have adopted requirements for clinical trial coverage 
have addressed it through legislation and a majority of these mandate coverage limit 
the mandate to cancer.  Once again this appears to be due to the political force of 
cancer and the fact that many third party payers already cover these expenses for 
cancer so that such a mandate does not create much additional cost to insurers.  The 
states that require third party payer reimbursement for routine medical care costs are: 
Arizona, California, Delaware, Georgia, Illinois, Louisiana, Maine, Maryland, 
Massachusetts, Missouri, New Mexico, New Hampshire, North Carolina, Ohio, 
Rhode Island, Vermont, and Virginia.56  New Jersey and Michigan have formed 
voluntary agreements with their third party payers and Connecticut passed legislation 
regarding the third party payers under its jurisdiction because attempts to work out a 
voluntary agreement were unsuccessful.  
                                                                
55Of the states that have these laws: Florida, Massachusetts, Minnesota and New 
Hampshire require that any basic health insurance package reimburse for this treatment; 
Georgia, Missouri, New Jersey, Tennessee and Virginia require this as a coverage option but 
allow the insurer to charge more for premiums that cover this treatment; Kentucky requires 
that any policy that covers high dose chemotherapy for breast cancer also covers bone marrow 
transplants when the standard chemotherapy has not been effective.  See Carla Piaza, 
Mandated Benefits: Coverage of Experimental Treatment/Clinical Trials, National Conference 
of State Legislatures Health Policy Tracking Service (July 3, 2000). 
56Carla Piaza, Mandated Benefits: Coverage of Experimental Treatment/Clinical Trials, 
National Conference of State Legislatures Health Policy Tracking Service (July 3, 2000). 
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1.  Connecticut: A Long and Winding Road 
Connecticut began to examine the issue of mandated coverage for routine patient 
care in clinical trials in its 2000 session of the Connecticut General Assembly and 
passed legislation mandating coverage for cancer only in 2001, and the story reveals 
some of the disadvantages of this state by state approach.  In the 2000 session of the 
Connecticut General Assembly, the Joint Committee on Insurance and Real Estate 
raised bill 580, An Act Concerning Clinical Trials for Cancer Patients, at the request 
of State Senator Edith Prague.57  After the bill was raised as a result of this request it 
was evident that the bill was significantly flawed.58 
Senator Prague testified at the public hearing on the bill and noted that the 
language was in dire need of amendment.59  When she left the hearing after her 
testimony, Senator Prague was approached by Mr. Donald Roll of Anthem BCBS of 
Connecticut who asked if she might consider voluntary action by health insurers an 
acceptable solution to this problem, at least temporarily, rather than an immediate 
legislative mandate.60  Mr. Keith Stover of the Connecticut Association of Health 
Maintenance Organizations also expressed support for the voluntary approach.  
Senator Prague was willing, especially in light of the short session and the flawed 
nature of the pending legislation, to explore the option of a voluntary agreement.61 
Shortly after the 2000 session of the General Assembly ended, Senator Prague 
began the Clinical Trials Task Force which held it first meeting on June 7, 2000 – the 
same day that President Clinton issued the Declaration regarding Medicare.  At the 
June 7 meeting it was not clear that the agreement would cover cancer only,62 but by 
                                                                
57In the even year “short session” individual legislators can only propose bills that relate to 
the budget and taxes.  Committees, however, can raise bills on any subject germane to them 
and often bills are raised by committees due to an individual legislator’s request to a 
committee chair. 
5813.2(C) 27580, 2000 Gen. Assem., Short Sess. (Conn. 2000).  Sec. 1 addresses 
individual health insurance policies; section 2 addresses group health insurance policies.  
Problems with the bill included a statement that insurance plans cannot deny coverage for any 
“procedure, treatment, or use of any drug as experimental” if it is in phase I, II, or III or a 
clinical trial for cancer treatment.  This does not describe routine medical care costs for 
clinical trial patients and could be interpreted to require third party payers to cover even costs 
directly related to the clinical trial such as the cost of the experimental drug itself.  Clearly, 
that was not the intent of Senator Prague or anyone else advocating for this type of legislation.  
The bill then states that, “If a drug is the subject of a clinical trial that a pharmaceutical 
company or other drug sponsor is required to complete to obtain approval for the drug by the 
federal Food and Drug Administration, such coverage shall not be required and the 
pharmaceutical company or sponsor shall pay for the drug and related care”.  This language is 
somewhat unclear regarding the meaning of “related care.”  It is possible to interpret this 
language to include routine medical care costs for clinical trial patients definitively within the 
responsibility of the trial sponsor.  This also was not the intention of Senator Prague. 




62See meeting minutes available from Connecticut State Senate Democrats 
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the second meeting it was settled, with no explanation, that the voluntary agreement 
would only address cancer trials, despite some objections.  The consultant hired to 
assist in the drafting of the agreement was funded by the American Cancer Society.  
In the second meeting on July 19, a steering committee was selected to draft the 
agreement to be presented to the entire task force at a later date.63  This meeting was 
originally scheduled for September 20, 2000, but was postponed due to 
disagreements over the language.  The working group, heavily weighted towards the 
third party payers, did agree to wording for the agreement on December 4, 2000, but 
the language was totally unacceptable to many members of the Task Force.  The 
language that the working group proposed would have provided a better tool for 
denying coverage than for expanding it.  The defects included limiting coverage to 
phase III of prevention trials, and specifically denying coverage of single institution 
trials conducted solely under the approval of the Institutional Review Board (IRB) of 
that institution.64  Although other disease organizations asked to be included in the 
process, these requests were denied.65  The working group went back to work but 
was unable to draft an agreement before the legislature was back in session.  In the 
meanwhile, Connecticut’s largest HMO, Physicians Health Services (PHS), 
announced that it was changing its policy and would now cover routine patient care 
for cancer clinical trials.66  Perhaps with the knowledge that this will soon be 
required, PHS presented a statement that allows it to control, for the moment, the 
language of it own coverage of these expenses.  PHS now covers routine care for 
patients enrolled in cancer trials approved by the NIH, the FDA, the VA and the 
DoD.  It is limited to cancer. 
Senate Bill 325, An Act Concerning Health Insurance Coverage During Clinical 
Trials, was raised by the Public Health Committee early in the 2001 session.  It 
included many of the same flaws as the working group’s draft of the voluntary 
agreement.  The bill required third party payers to cover routine care in clinical trials 
for cancer only.  The bill required coverage for phases I, II, and III of treatment trials 
but only phase III of prevention trials. There is a limitation that the mandate does not 
cover single-site trials. The mandate is broad by sponsor; it requires coverage for 
trials approved by NIH, the FDA, the VA, DoD, and National Cancer Institute 
cooperative groups. 
At the March 1, 2001, public hearing on this bill representatives for the 
Connecticut State Medical Society and the Connecticut chapter of the National 
Multiple Sclerosis Society testified on the need to extend this mandate beyond 
                                                                
63The author was in attendance at the July 19, 2000 meeting.  This information is also 
available in the meeting minutes. 
64This draft is not published, but is available from the author. 
65Specifically, Betty Gallo who is the lobbyist for the MS Society as well as several other 
disease organizations approached the task force. 
66See http://www.phshealthplans.com/news/nycancer.html  
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cancer.67  Some members of the Public Health Committee did express concerns with 
the cancer-only limitation.68 
After the hearing, Senator Prague agreed to hold a meeting with lobbyists from 
the HMOs and representatives of the Multiple Sclerosis Society.69  The HMO 
lobbyists stated their strong opposition to expanding the bill and stated their intent to 
oppose the bill if it was expanded.  After a lengthy and at times heated discussion, 
the HMO lobbyists made several small concessions: They agreed to make clear that 
the paperwork requirements in the bill would pertain only to cancer trials as that was 
the only coverage mandated by the bill and they also agreed that there could be a 
statement on the floor, written by HMO lobbyists and the MS Society, for the 
purposes of legislative intent that there was no intent to have a harmful effect on 
clinical trials not covered by the bill.  In addition, they agreed to meet in good faith 
after this session to discuss expansion of the mandate.  The MS Society 
representatives were clear that they wanted the coverage expanded to clinical trials 
for all serious diseases, not just for MS.  They had planned to invite representatives 
from other disease organizations both because this is a more rational policy and 
because there is strength in numbers.  SB 325 did pass, but unfortunately, the MS 
society got nervous because some of their funding comes from HMOs and they 
cancelled the plans to work for expansion of the mandate.  If a bill similar to the 
McCain/Kennedy Bipartisan Patient Protection Act passes Congress, these 
discussions will be moot.   
The power of the HMO lobbyists in controlling legislative action in Connecticut 
on this issue is disconcerting; this description of the recent happenings in 
Connecticut offers support for the usefulness and efficiency of a national standard.  
The likelihood that there will be 50 such struggles with successful results is slim.  
One plan in Congress could affect all third party payers, would require only one 
fight, and would result in far more security for patients interested in clinical trial 
participation. 
2.  State Coverage Beyond Cancer 
Maryland, Maine, New Hampshire and North Carolina all mandate coverage for 
routine care costs in clinical trials for cancer or “other life threatening diseases.”  The 
mandates from these four states present small variations, but what is left unanswered 
by the text of all four state statutes is what “life-threatening” includes.  The 
interpretation of this term will determine how effective the legislation will be in 
encouraging the development of new effective therapies for rare diseases which are 
                                                                
67See the Public Health Committee transcripts from March 1, at http://www.cga.state.ct.us; 
Dr. Michael Saffir testified for the Connecticut State Medical Society and Dr. Timothy 
Vollmer as well as the author testified for the Multiple Sclerosis Society.  
68Representative Winkler expressed concerns during the hearing and Sen. Harp shared her 
concerns with the author after the hearing. In fact at the hearing after Dr. Saffir testified on 
behalf of the Medical Society, Rep. Winkler expressed her understanding that the bill had been 
meant to affect all clinical trials and suggested that it might be possible to remove the word 
cancer.  She was not correct and this was not done. 
69The attendees were Sen. Prague, Mr. Keith Stover, Mr. Don Roll (HMO lobbyists), Dr. 
Timothy Vollmer, Attorney Shelley Marcus, Ms. Sharon Finn, Ms. Susan Raimondo, Ms. 
Betty Gallo (representing the MS Society), and the author. 
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not now, due to the small numbers of patients, attractive diseases for study.  The 
breadth of the mandates will rest with the definition of this term whether through 
regulation or case law. 
The broadest and most comprehensive state legislation is the Maryland Clinical 
Trials Act (MCTA).  The Maryland mandate covers all phases of clinical trials, and a 
broad range of public and private sponsors.70  Maryland is the home of the NIH, and 
generally friendly to research.  
In 2000 Maine enacted a law which mandates coverage of routine patient care in 
clinical trials for cancer and other life threatening diseases.71  The Maine statute, like 
the MCTA, has no restrictions regarding the phase of the trial.  However, the 
mandate by the Maine law narrows the potential impact of the legislation because it 
severely restricts the required coverage by trial sponsor.  Maine’s form of caution 
should provide a more sensible outcome than most of the states that have adopted 
this mandated coverage but limit the impact on third party payers by limiting 
coverage to the already protected cancer trials instead of limiting by trial sponsor.  
Additionally, New Hampshire requires coverage of routine patient care costs for 
clinical trial patients in clinical trials for cancer or other life threatening diseases.  
While the scope of the New Hampshire law is broad in terms of sponsor, an 
ambiguous provision may limit the mandate by phase.72  Another interesting note is 
that this New Hampshire legislation also contains a provision to study coverage of 
bone marrow transplantation. 
                                                                
70See MD INS. CODE ANN., [Insurance] § 15-827 (2002).  The Maryland law requires all 
insurers and managed care organizations to cover routine care costs incurred in all phases of 
qualified clinical trials for cancer or other life threatening conditions.  The legislation affects 
all trials approved by the NIH, an NIH cooperative group, the FDA in the form of an 
investigational new drug application, the VA, or an institutional review board of an institution 
in the state which has a multiple project assurance contract approved by the Office of 
Protection from Research Risks of NIH. In order to be deemed a ‘qualified’ clinical trial, the 
investigators must possess sufficient expertise and experience, there must be no clearly 
superior standard treatment, and there must be a reasonable expectation from clinical or 
preclinical data that the treatment will be at least as effective as standard therapy. An entity 
seeking coverage under the provision mandating coverage for investigations approved by a 
state IRB must also keep an updated list that is posted electronically citing the phase of the 
trial, the approving entity, the disease which is the subject of the trial, and the number of 
participants in the trial.   
The MCTA uses the term “patient care” for routine care and defines these costs as the 
“cost of a medically necessary health care service that is incurred as a result of the treatment 
being provided to the member for purposes of the clinical trial.”  The MCTA specifically 
excludes the cost of the investigational drug or device and costs associated with managing the 
research associated with the clinical trial.  The MCTA definition is broad and similar in scope 
to the IOM proposal. 
71See 2000 Me. Legis. Serv. 24A § 4310 (West). The Maine law mandates coverage of 
patient care expenses in approved clinical trials for a life threatening illness for which no 
standard treatment is effective.  The Maine statute has no restrictions regarding the phase of 
the trial, but for mandated coverage to apply to the trial, it must be approved and funded by the 
NIH (or a cooperative group or center) or the Department of Health and Human Services.  The 
Maine statute includes far less detail than the MCTA. 
722000 N.H. Laws § 415:18-k This legislation has an internal conflict.  The New 
Hampshire law states that it requires coverage for Phases I, II, III and IV and then states that a 
case by case review should be done to determine coverage for Phases I and II. 
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North Carolina enacted a law in its 2001-02 session which required coverage for 
treatment of life threatening medical conditions.  The North Carolina law requires 
coverage for phases II, III, and IV of trials.  Its sponsorship requirements are broad; 
it requires coverage of trials sponsored by NIH, NIH cooperative group of center, the 
Food and Drug Administration, The Centers for Disease Control and Prevention, the 
Agency for Healthcare Research and Quality, The Department of Defense, and the 
Department of Veterans Affairs.73 
Although the statutes in the four states that mandate coverage of routine patient 
care costs in clinical trials vary from each other only slightly, all the legislation is so 
new that the effects are not yet known.  Studying the differences in impacts on third 
party payers in each of these three states should provide useful data to other states 
considering this kind of legislation and to congress if, as is likely, the patients rights 
issue rises again in the 108th congress. 
3.  States That Mandate Coverage For Cancer Trials Only 
Five states mandate coverage for routine patient care in clinical trials for all types 
of cancer through legislation: Rhode Island,74 Arizona,75 Louisiana,76 California,77 
and Virginia.78  New Jersey and Michigan79 have voluntary agreements with their 
insurers to cover routine patient care in cancer trials.  As with the states that mandate 
coverage beyond cancer, there is some variation in the coverage required. 
Rhode Island, the first state to enact mandated third party payer coverage for 
routine patient care in clinical trials, requires coverage for Phases II, III and IV of 
NCI authorized trials where there is no clearly superior approved therapy. 
The Virginia law requires slightly broader coverage than that required in Rhode 
Island.  It requires third party payer coverage for routine patient care in Phase II, III, 
and IV of cancer trials with no differentiation regarding Phase II.  Virginia’s statute 
additionally provides for a case-by-case review for Phase I trials. 
Louisiana, like Rhode Island, required coverage of routine patient care in Phase 
II, III, and IV for cancer clinical trials.  There is no provision in Louisiana’s law 
regarding Phase I and the trial must meet additional criteria.80 
                                                                
73See North Carolina Session Law 2001-446.  Part III, Subpart A. 
741997 R.I. Pub. Laws § 27-18-36.2 (The Rhode Island statute does not mandate Phase I 
coverage and contains no explicit definition of routine care. It also states that in Phase II trial 
costs customarily borne by the sponsor will remain with the sponsor). 
752000 Ariz. Legis. Serv. 371 (West). 
76L.A. REV. STAT. ANN. § 22:230.4 (West 2000). 
77See CA Senate Bill 37, signed August 9, 2001.  See also http://www.nci.nih.gov/ 
clinicaltrials/developments/laws-about-clinical-trial-costs.  Medicaid is also mandated to cover 
these costs in CA. 
78V.A. CODE ANN. § 2.1 - 20.1 (LEXIS 2000). 
79See http://www.nci.nih.gov/clinicaltrials/developments/laws-about-clinical-trial-costs. 
80These additional requirements include that the entity seeking coverage must post 
electronically an up to date list including: the phase for which the trial is approved, the entity 
approving the trial, the type of cancer being studied in the trial, and the estimated number of 
participants. 
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In 2000 Arizona joined the list of states that mandate third party payer coverage 
for routine patient care in cancer clinical trials.  Arizona’s law is the broadest of the 
“for/cancer/only” clinical trial legislation; it mandates coverage for Phases I, II, III, 
and IV.  Arizona does not provide for any coverage beyond cancer.  California,81 
Delaware,82 Massachusetts83 and New Mexico84 have all followed suit with mandates 
that are broad in terms of sponsorship but cover only cancer clinical trials.  New 
Mexico’s law sunsets July, 2004. 
Three states, Georgia,85 Missouri,86 and Illinois87 have passed even more cautious 
forms of “for/cancer/only” mandated clinical trial coverage.  Georgia mandates 
coverage only for pediatric oncology trials, Illinois allows a benefit limit, and 
Missouri offers coverage severely limited by phase. 
Georgia’s statute requires third party payers to cover routine patient care only in 
Phases II and III.  The requirement applies to drug trials in pediatric oncology—no 
devices, no adults.  While the horror of child cancer is undeniable, the logic of this 
policy is unclear.  It may be justifiable to offer additional support for children, but 
there does not seem to be a reason to cover drug but not device trials, nor does it 
seem sensible to deny this coverage for other devastating pediatric diseases.  
Missouri only covers phases II and III but is broad by sponsor. 
Illinois takes a different tack in further limiting the mandated coverage.  It 
requires that third party payers must offer coverage for routine patient care in Phases 
II, III, and IV of cancer clinical trials.  However, the insurers can set benefit limits at 
$10,000 per year.  Additionally, the law has a sunset provision which repeals the law 
on January 1, 2003, unless the legislature acts to provide for its continuation.  The 
Illinois legislature is obviously concerned about the potential effects of these 
provisions and has sought to limit the effect and scope. 
Vermont and Ohio limit their coverage in ways that favor the specific state.  
Vermont88 passed legislation that covers trials administered at a Vermont hospital, a 
qualified Vermont cancer care provider, and clinical trials under the auspices of two 
specified cancer care centers.  The law sunsets in 2005.  Ohio89 has a very limited 
                                                                
81See supra note 77.  See also http://www.nci.nih.gov/clinicaltrials/developments/laws-
about-clinical-trial-costs. 
82SB 181 of 2001 session effective January, 2002.  See also http://www.nci.nih.gov/ 
clinicaltrials/developments/laws-about-clinical-trial-costs. 
83HB 4376 of 2002 session. Chapter 257 of 2002 session.  Effective January 2003.  See 
also http://www.nci.nih.gov/clinicaltrials/developments/laws-about-clinical-trial-costs. 
84SB 240 effective March 14, 2001. See also http://www.nci.nih.gov/ 
clinicaltrials/developments/laws-about-clinical-trial-costs. 
852000 GA. LAWS 33-24-59.1 (West 2000).  See also http://www.nci.nih.gov/ 
clinicaltrials/developments/laws-about-clinical-trial-costs. 
86SB 1026 effective August 28, 2003.  See also http://www.nci.nih.gov/clinicaltrials/ 
developments/laws-about-clinical-trial-costs. 
87215 ILL. COMP. STAT. ANN. 5/356y (West 2000). 
88HB 255 effective March 1, 2002.  See also http://www.nci.nih.gov/clinicaltrials/ 
developments/laws-about-clinical-trial-costs. 
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plan.  It mandates coverage only for Ohio state employees who are insured by Ohio 
Med Plan and are enrolled in phase II and III NCI sponsored trials. 
New Jersey has tried a new approach for states: A voluntary agreement by the 
insurers in the state to provide coverage for routine patient care in all phases of 
cancer clinical trials.90  This agreement was signed in the fall of 1999 and the effects 
are not yet known.  The agreement does not offer the protection that legislation 
would; the only protection would come from language in the policies offered by the 
state’s insurers.  The insurers may be hesitant to violate the agreement for fear that 
violations could lead to more demanding legislation on this issue.  More recently 
Michigan has also negotiated a voluntary agreement.91 
Nationally, there has been some effort at voluntary agreements between insurers 
and the government.  The American Association of Health Plans in a 1998 
agreement with NIH recommended that its member plans cover routine patient care 
in cancer trials.92  There are a number of plans that have forged agreements with NIH 
perhaps as a result of this recommendation.93  These voluntary agreements tend to 
limit the risk to the third party payer. 
VII.  WORDS OF CAUTION ON RESEARCH REGARDING HUMAN SUBJECTS 
The possibilities raised by increasing the number of clinical trials for rare 
diseases is exciting, but it is important not to lose sight of the sometimes frightening 
history of research on human subjects.  This history suggests that there must be 
sufficient oversight of any research on human beings. 
A.  A Brief History 
Two of the most notorious ethical violations in research on human subjects, each 
of which led to reform are:  The Nazi doctors convicted at Nuremberg who had 
performed unthinkable “experiments” on concentration camp prisoners,94 and the 
Tuskeegee Human Syphilis study in the United States from 1932 to 1972, in which 
the course of untreated syphilis was observed in 400 African-American men—the 
“study” continued and the subjects were not offered treatment even after effective 
treatment was available.95 
                                                          
89See http://www.state.oh.us/das/dhr/hcb/hcb14.html.  See also http://www.nci.nih.gov/ 
clinicaltrials/developments/laws-about-clinical-trial-costs. 
90Available at http://www.state.nj.us/governor/news/p91217a.htm. 
91See www.nci.nih.gov/clinicaltrials/developments/law-about-clinical-trial-costs-
michigan. 
92AAHP Board of Directors Agreement Between AAHP and NIH for Support of Clinical 
Trials (1998), available at http://aahp.org. 
93Available at http://www.clinicaltrials.gov.  
94See United States v. Karl Brandt, Military Tribunal Case No. 1, 1947 (Nuremberg). See 
Also ALBERT JONSEN, The Ethics of Research with Human Subjects: A Short History, 5-10  in 
SOURCE BOOK IN BIOETHICS (Albert R. Jonsen et al., eds), Georgetown University Press, 
1998).   
95In 1972, the story of the Tuskeegee Syphilis Study was exposed to the public by the 
media.  From 1932 until the story broke in 1972, 400 African-American men with syphilis 
living in rural Georgia were denied treatment so that researchers could watch the progression 
of this disease untreated.   The horrified reaction to the truths of the Tuskegee study led to the 
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Internationally, the origin of the rules and regulations that govern modern 
research on human subjects can be traced back to the ten point Nuremberg Codes 
which originated from the verdict against the Nazi doctors. The Nuremberg Codes 
led to the Helsinki Declaration which generalized the Nuremberg Codes to make 
them more relevant to general research.  The Helsinki Declaration emphasizes 
informed consent, respect for persons, and risk-benefit analysis.96  
After World War II, there was an extraordinary increase in government funding 
of research in the United States, but there was no organized and uniform review 
mechanism.97  The prevailing sentiment in the medical community was that patient 
interests were best served by the inherent ethics of the researchers; the medical 
community did not view the Nuremberg Codes as relevant to the research in the 
United States.  A few lone voices dissented, and history has shown these voices to be 
prophetic.98   
More recently, there was an additional discovery: from 1944 to 1974 the 
government had sponsored a number of radiation experiments on citizens. Once 
again, an advisory panel was convened to research the scope of these ethical 
violations and recommend changes in the oversight mechanisms.99  Again, this came 
at a time of extraordinary growth in the experimentation on human subjects, and the 
panel made suggestions not only regarding classified research but also specifying the 
need for reform in research on human subjects generally.  It is clear that the ethical 
struggles in research on human subjects are not resolved.  The report on the Human 
Radiation Experiments100 in combination with the recent ethical violations in gene 
                                                          
creation of the Tuskegee Syphilis Study Ad Hoc Advisory Panel and ultimately the Belmont 
Report which recommended specific reforms to the oversight of research on human subjects.  
A significant number of the suggested reforms were enacted, and these constitute the core of 
46 CFR 45 which governs the ethics of research on human subjects.  One of the most 
important pieces of these regulations is the requirement that research of human subjects be 
approved by an Institutional Review Board (IRB).  The regulations include requirements 
regarding the kind of monitoring the IRB must perform after approval of a project and also 
provide requirements regarding IRB membership. 
96Id. The Helsinki Declaration was the product of the World Medical Association in 1964.  
It has been amended several times.  See also GEORGE ANNAS, THE RIGHTS OF PATIENTS 144-45 
(Southern Illinois University Press 1989) and Furrow et al. Health Law, ch. 21 § 6 (Hornbook 
Series, 2nd ed. West 2000). 
97ALBERT JONSEN, SOURCE BOOK IN BIOETHICS 13 (1998). 
98Id. 
99Many of these experiments did not fall under the requirements of 46 CFR 45 because 
they were “classified.”  The panel was stunned by the large number and variety of experiments 
and ultimately produced approximately 5,000 pages of reports.  Available at 
http://tis/eh/doe.gov/ohre/roadmap/achre. 
100The release of this report has also spawned a number of court cases, some of which 
have been successful, brought by the unsuspecting victims of these experiments.  See e.g., In 
Re Cincinnati Radiation Litigation, 874 F. Supp 796 (S.D. Ohio 1995); Craft v. Vanderbilt 
Univ., 18 F. Supp. 2d 786 (M.D. Tenn. 1998); and Bibeau v. Pacific Northwest Research 
Found. Inc., 188 F.3d 1105 (9th Cir. 1998).  The earlier rulings that soldiers cannot recover 
damages for experiments performed on them have not yet been overturned.  See Jaffee v. 
United States, 663 F.2d 1226 (3rd Cir. 1981) and United States v. Stanley, 483 U.S. 669 
(1987).  There were strong dissents in both cases. 
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therapy (which led to the death of a young man who should not have been enrolled in 
the trial at all)101 and cancer research102 led the 106th Congress to propose reforms 
which unfortunately did not pass.103  There have been a few even more recent 
problems such as the violations of required protocol at the Fred Hutchinson Cancer 
Research Center that were exposed by the Seattle Times,104 and the recent death in 
an Asthma Study funded by NIH and conducted at Johns Hopkins105 as well as the 
recent Johns Hopkins study that exposed healthy children to lead paint.106  Policy 
changes that are likely to increase the number of clinical trials such as mandating 
coverage of routine patient care costs must be watched closely to prevent potential 
ethical lapses. 
B.  Contemporary Issues 
The remarkable growth in experiments on human subjects has left the current 
system of regulation unable to perform adequately.  The ethical issues of informed 
consent by patient enrollees and respect for the patients as well as complete 
disclosure of risks to them remain at the forefront of the ethical requirements of 
clinical trials, but there are also new issues.  Currently, the IRBs are overworked and 
are not able to monitor adequately all the trials for which they are responsible.107  
This is a direct result of the dramatic increase in clinical research.  One of these new 
ethical issues is the problem of doctors with financial conflict-of-interest (doctors 
who are researchers and have an equitable interest in the sponsor company108 or who 
get a bonus from the company-sponsor for enrolling their own patients in the trial).109  
The increasing involvement by private companies in new drug development created 
the potential for this conflict of interest.  This problem could become even more 
difficult to regulate with an increased number of trials which could be a result of 
mandating coverage of routine care in clinical trials. 
Additionally, a new type of IRB has evolved due to the private for-profit 
sponsorship of clinical trials: The independent IRB.  This kind of IRB is increasing 
in number.  Independent IRBs are not local and are not attached to a specific 
                                                                
101Eliot Marshall, Gene Therapy on Trial, 288 SCIENCE 951-57 (2000). 
102David Malakoff, Flawed Cancer Study Leads to Shake-up at Univ. of Oklahoma, 289 
SCIENCE 706-07 (2000). 
103H.R. 4605, 106th Cong. (2000). 
104Duff Wilson, Uninformed Consent, SEATTLE TIMES, Mar. 11-15, 2001 at A1.  (Doctors 
in these studies had financial conflicts of interest with the pharmaceutical companies that were 
the trial sponsors). 
105Susan Levine, FDA Cites Flaws in Hopkins Asthma Study, WASH. POST, July 3, 2001, at 
B03. 
106Grimes v. Kennedy Krieger Institute, 782 A.2d 807 (MD. 2001) 
107Beverly Woodward, Challenges to Human Subject Protections in US Medical Research,  
282 JAMA  1947, 1947-52 (1999).  
108Philip Hilts, U.S. Weighs Changes on Rules in Drug Research Conflicts, N.Y. TIMES, 
August 16, 2000, at A28. 
109Office of the Inspector General, Recruiting Human Subjects:Pressures in Industry 
Sponsored Research, OEI-01-97-00195 (June, 2000). 
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institution, as are traditional IRBs.  Many of these independent boards are for-profit 
entities.110  These entities create the possibility for numerous ethical conflicts not the 
least of which is the possibility of IRB “shopping.”  This possibility, that a for-profit 
company sponsor can search for a for-profit IRB that will permit the protocol most 
favorable to the sponsor, raises obvious concerns.  If both the sponsor and the 
monitoring board are for-profit entities, is patient protection anyone’s top priority?  
One of the reforms that the 106th Congress proposed but did not pass would have 
required all IRBs to be accredited by a not-for-profit entity.111 
The lure of care and treatment within the context of clinical trials to the 
uninsured and underinsured patients with serious diseases presents ethical issues of 
increasing magnitude as the number of available clinical trials expands and our 
nation does not provide universal health care coverage.  This is a concern not only 
for those with involvement in clinical trials but also for our entire society — it is 
unethical to place a disproportionate burden for drug discovery on those who have 
limited treatment options.112 
VIII.  CONCLUSION  
The need to find new and better treatment options seems an obvious one, and it is 
clear that clinical trials are an important part of this process.  The question remains, 
what is the best public policy to encourage this? 
One current avenue of choice in mandating coverage — mandating coverage for 
cancer only is disturbing.  This is poor public policy; it does not resolve the most 
pressing need first.  While it would be most desirable to provide coverage for routine 
care for clinical trial enrollees for all qualified clinical trials, if there is a need to take 
a step by step approach, cancer-only is not the right first step.  If an incremental 
approach is warranted, there are more rational cautious methods.  Mandated 
coverage for routine patient care in clinical trials for rare diseases should come first.   
Another possible cautionary provision would be a mandatory review of the 
legislation’s consequences after a set term of two or three years.  An alternative 
possibility would be to limit the mandatory coverage to publicly sponsored trials, at 
least until there is clear data that this coverage did not present an unmanageable 
burden on the third party payers; that was Congress’ approach in its proposals.  
However, there does not appear to be evidence that the routine care costs are 
significantly higher for trial patients than for patients receiving standard treatment.   
The promise of this policy is that if followed it will lead to more treatments 
(especially for rare diseases if they are included).  This promise will need to be 
monitored both to ensure that the sponsors are not simply using this as easy money 
with no responsibilities attached and to ensure that it does not lead to an increased 
number of lower quality trials.  This is particularly important if private trials are 
included in the mandate. 
                                                                
110Office of the Inspector General, Institutional Review Boards: The Emergence of 
Independent Boards, OEI-01-97-00182 (June, 1998). 
111H.R. 4605, 106th Cong. (1999). 
112Sugarman, J. et al., What Patients Say About Medical Research, 20 IRB 4, 107 (1998).  
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A federal mandate on this issue would create the best public policy — a uniform 
law across country would satisfy the goal of reducing insecurity of trial patients 
regarding expenses.  A national standard would provide one consistent definition of 
the terms such as routine patient care.  The legislation should go beyond cancer to all 
qualified clinical trials or at least to trials for serious or life threatening conditions; 
insurers often cover routine care in cancer trials now anyway — through public 
private partnerships and NIH cooperative groups.  There is serious need for clinical 
trials testing therapies for rarer diseases which often lack any treatment and do not 
have enough patients to make it profitable enough to encourage a drug company’s 
effort—one of the unfortunate effects in this for-profit system.  The trials may be 
prohibitively expensive for public research entities if they must pay all routine 
patient care costs.  
Legislation would offer greater protection than voluntary agreements; legislation 
can be enforced and can include penalty provisions for companies that do not follow 
the requirements.  It would be appropriate to monitor the effects of any legislation on 
this issue to discover whether the policy created an increased number of clinical 
trials and new therapies as well as to discover what the financial effects have been.  
This monitoring is easier with federal legislation because federal agencies fund or 
approve the trials.  If Congress does not act on this and the states choose to act, or if 
the states choose to mandate broader coverage than Congress does, legislation is a 
better option for the same reason: Enforceability. 
In the realm of Medicare, the administrative action option has many good 
qualities: the mandated coverage was broad and the effect was immediate.  The 
problem with an administrative order is that if the next president does not agree with 
the policy, it could all be undone just as quickly and leave the Medicare recipients in 
their former conundrum.  For this reason it would be rational to pass legislation to 
back up the Declaration. 
While the move towards for-profit health care coverage appeared to decrease the 
third party payer coverage of routine care in clinical trials, the recent attention to 
problems in our healthcare system seems to have brought attention to this issue.  In 
the next few years it is likely that the coverage for these costs will again increase as a 
result of some form of government action. 
It is of extraordinary importance that patients know from the start what the 
expenses and risks are and that they know they will not be abandoned after 
participating in research studies.  There must be no question that patient protection is 
the top priority for all research on human subjects.  The system for assuring patient 
protection needs updating as well, especially if new requirements mandating third 
party payer coverage for routine care in clinical trials spawns an increased number of 
trials.  Protection for clinical trial enrollees must include disclosure and 
understanding of risks, strict reliance on ethical practices and also security regarding 
how costs will be borne.  One national standard could ensure the protection of 
subjects both medically and financially. 
